MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Antidepressants"

  • 2024 International Congress

    Comparison of Age, Cognitive, Autonomic, and Motor Testing between Serotonergic vs Idiopathic REM-Sleep Behavior Disorder

    M. Berns, N. Reddy, H. Olson, R. Berns, M. Howell (Minneapolis, USA)

    Objective: To compare the age, cognitive, autonomic, and motor function of REM-Sleep Behavior Disorder (RBD) patients amongst those who believe their symptoms were triggered by…
  • 2024 International Congress

    Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson’s Disease Case Study with Concomitant Refractory Major Depressive Disorder

    D. Nolasco, L. Schmidt, B. Carr (Gainesville, USA)

    Objective: This investigation delineates the pharmacokinetic intricacies encountered in the therapeutic management of a geriatric patient with Parkinson’s Disease (PD) concomitantly suffering from refractory Major…
  • 2024 International Congress

    Acute dystonic dyskinesias in a patient used fluvoxamine. Case report

    A. Katok, D. Khasanova, G. Ilina (Kazan, Russian Federation)

    Objective: To represent a case of acute dystonic dyskinesias after fluvoxamine use by the patient with obsessive thoughts and movements. Background: In psychiatric clinical practice,…
  • 2024 International Congress

    Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report

    H. Oktaviani, A. Tiksnadi, D. Tunjungsari (Jakarta, Indonesia)

    Objective: To underscore the rarity of tardive dyskinesia manifestation in a schizophrenic patient, prescribed second-generation DRBA agents, quetiapine and SSRI sertraline. Background: Tardive dyskinesia is…
  • 2024 International Congress

    Improving Neuropsychiatric Comorbidity in Geriatric Spinocerebellar Ataxia

    M. Le, B. Carr (Gainesville, USA)

    Objective: This study evaluates neuropsychiatric comorbidity in spinocerebellar ataxia (SCA) and highlights key aspects of management in the geriatric population. It discusses efficacy of neuropsychotropic…
  • 2023 International Congress

    Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease

    T. Falk, S. Richards, M. Bartlett, A. Lind, C. Hsu, S. Sherman (Tucson, USA)

    Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…
  • 2023 International Congress

    Clinical features and phenoconversion risk in women with isolated REM sleep behavior disorder

    C. Alexandres, S. Mccarter, G. Tabatabai, L. Leclair-Visonneau, J. Feemster, T. Gossard, P. Timm, D. Sandness, J. Jagielski, E. Strainis, D. Carvalho, M. Junna, M. Lipford, J. Moore, M. Tippmann-Peikert, M. Silber, B. Boeve, E. ST. Louis (Rochester, USA)

    Objective: To determine features predictive of differential phenoconversion rates in isolated REM sleep Behavior Disorder (iRBD) to a defined neurodegenerative disease (NDD). Background: iRBD is…
  • 2023 International Congress

    The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative

    N. Dahodwala, D. Weintraub, M. Bock, R. Cho, C. Caspell-Garcia, E. Brown, R. Dobkin (Philadelphia, USA)

    Objective: To determine the functional consequences of baseline anxiety symptoms and the longer-term impact of initiation of anxiety treatment in Parkinson’s disease (PD). Background: While…
  • MDS Virtual Congress 2021

    Acute functional movement disorder in a Lupus patient

    D. Rebolledo, J. Diestel, I. Reyes (Mexico City, Mexico)

    Objective: Movement disorders (MD) in autoimmune diseases are uncommon. However, the initial presentation required that the clinicians characterize the clinical phenomenology. Rheumatological patients' complexity required…
  • MDS Virtual Congress 2021

    Potential drug-drug interactions in hospitalized patients with Parkinson’s disease from tertiary center in Serbia

    D. Aleksic, S. Stefanovic, M. Milosavljevic, J. Milosavljevic, S. Jankovic (Kragujevac, Serbia)

    Objective: The aim of this study was to identify predictors of potential drug-drug interactions in patients suffering from Parkinson’s disease.The aim of this study was…
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley